web analytics
5.7 C
Munich
Sunday, October 17, 2021

Powerful Run on Enzolytics, Inc. (ENZC); Biotech Producing anti-SARS-CoV-2 Monoclonal Antibodies

Enzolytics, Inc. (ENZC) is rocketing up the charts on a powerful surge of 10s of millions of dollar volume daily since a brief dip below the $0.25 mark on Thursday. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. 

It is becoming increasingly evident that Coronavirus vaccines are not as effective against newly discovered variant of the virus as scientists had hoped. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. Recently ENZC has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company’s genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed. The Company has filed a comprehensive patent application covering these discoveries.  

Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. ENZC has been rapidly building up an intellectual property portfolio filing numerous patents last year. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor – Pharmaceutical Composition for Treatment.”  Since than the ENZC has filed a number of new applications. The Company recently merged with BioClonetics Immunotherapeutics, Inc., now a wholly owned subsidiary of Enzolytics; a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases. 

Microcapdaily has been reporting on the ENZC BioColnetics merger since the beginning recenlty stating: “Enzolytics Inc. ENZC: is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirusEnzolytics has attracted a major league level management team behind it and has expanded its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Microcapdaily first reported on ENZC the day after the merger was announced in our article: “BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC)” on September 16 when ENZC was trading for well under $0.01  

Enzolytics has quickly attracted a power house team behind it which speaks of big things to come here. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board. Mr. Moss has been an executive with numerous biotech’s over the past 25 years. He has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA experience. The Company’s Chief Science Officer, Mr. Henry Zhabilov has managed several clinical trials utilizing therapeutic proteins. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform. 

https://twitter.com/Les1442/status/1367156174295040005

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

The newly combined Companies are led by CEO and majority shareholder Charles S. Cotropia, a well-known intellectual property attorney who has litigated over 200 patents in his career and served as lead counsel in several landmark patent disputes litigated in Federal Courts and the US Patent and Trademark Office. Mr. Cotropia founded BioCLonetics along with his brother Dr. Joseph Cotropia, MD, who pioneered BioCLonetics proprietary method for creating human cell lines that produce human antibodies directed against many infectious diseases. One cell (designated as CLONE 3) has been demonstrated in multiple tests and 5 Independent studies to neutralize the HIV virus in 98% of all known varieties world-wide.  

Several weeks ago, the Company executed Articles of Association to form International Medical Partners (“IMPL”) a Bulgarian Limited Liability Company of which the Company is 50% owner. The Company’s partners in IMBL are a group of successful Bulgarian businessmen who will fund the cost of the Clinical trials under the European Medicine Agency (the “EMA”) standards and the application cost for the EMA permit for the Company’s ITV-1 patented therapeutics for treating HIV. Under the Mutual Recognition Agreement (the “MRA”) between the EMA and the United States Federal Drug Administration (the “FDA”), the company believes that issuance of the EMA permit for the ITV-1 compound should qualify ENZC’s treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that may be required under EMA standards. As the Company progresses in its efforts to commercialize all the current and yet to be discovered opportunities of its licensed and patented treatments the addition of IMBL and the benefits of obtaining an EMA permit has opened up new and exciting avenues for growth of the ENZC and the associated potential increase in value to its shareholders. 

The Audits of the Company’s current and prior year Financial Statements are in process and the application for OTCQB is being prepared for submission upon issuance of the Audited Statements. The Company plans to complete the two-year audit as quickly as possible but will file the December 31, 2021 Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines. The Company anticipates filing the financial statements under the Basic Disclosure Guidelines for December 31, 2020 in the coming weeks before the filing deadline of March 31, 2021. 

ENZC recently identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company’s genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed. 

ENZC has filed a comprehensive patent application covering these discoveries. This initial application has been filed in the U.S. and will be extended to claim international patent coverage through the International Patent Cooperation Treaty (PCT) to which 153 countries subscribe. The patent coverage sought includes patent claims on the discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to the epitope/antigens. 

Before completing the Artificial Intelligence analysis of the 50,512 SARS-CoV-2 isolates to identify conserved epitopes, the Company’s scientists predicted a specific target epitope that is correlative in structure to the site on the HIV virus to which the Company has produced a monoclonal antibody that has been shown to neutralize the HIV virus. The prediction was that this site would be conserved as is the correlative site on the HIV virus. The AI analysis of the 50,512 SARS-CoV-2 isolates identified this predicted site on the virus as 99% conserved across all 50,512 isolates. This primary site on the SARS-CoV-2 virus has also been confirmed as existing (100%) in the U.S. SARS-CoV-2 virus and the virus variants which have surfaced in United Kingdom, Brazil and South Africa, which are now in the U.S. This epitope on the SARS-Cov-2 virus is included in the first being targeted by the Company in its production of epitope specific monoclonal antibodies. The Company’s focus is on producing monoclonal antibodies that target immutable sites to avoid “virus escape”. 

In addition to patenting Company’s findings of conserved sites on the SARS-CoV-2 (Coronavirus), the Company is also filing patent applications covering the conserved sites on the HIV virus. Filings will be made in the U.S. Patent Office and then extended for international coverage through the PCT covering 153 countries. 

As the Company has previously reported, it is also curating (analyzing) the amino acid sequences of other major viruses and will file patent applications claiming the identified antigens/epitopes and associated therapeutics. Using AI analysis, the Company is now identifying and will claim the conserved epitopes/antigens on the infectious diseases caused by HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV), Visna virus (VISNA) and mouse mammary tumor virus (MMTV). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens. 

https://twitter.com/azsportsfan13/status/1367899011403849729

For more on ENZC Subscribe Right Now!

Enzolytics, Inc. (ENZC) is rocketing up the charts on a powerful surge of 10s of millions of dollar volume daily since a brief dip below the $0.25 mark on Thursday. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19.  It is becoming increasingly evident that Coronavirus vaccines are not as effective against newly discovered variant of the virus as scientists had hoped. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. Recently ENZC has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company’s genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed. The Company has filed a comprehensive patent application covering these discoveries.  Since a brief dip Investors are looking for a powerhouse move back to recent highs; a break over $0.91 and its an all-out blue-sky breakout We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.